Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Post-COVID-19 Era
share announcement

Personalized Medicine in Post-COVID-19 Era

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 15 October 2024 | Viewed by 2680

Special Issue Editors

Prof. Dr. Cristian Oancea

E-Mail Website
Guest Editor
Pulmonology Department, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania
Interests: respiratory system; cognition; cardiovascular health
Special Issues, Collections and Topics in MDPI journals
Dr. Elena Cojocaru

E-Mail Website
Guest Editor
Morpho‑Functional Sciences II Department, Faculty of Medicine, “Grigore T. Popa" University of Medicine and Pharmacy, Iași, Romania
Interests: lung diseases; COVID-19; laboratory medicine; renin-angiotensin system; immunology; endocrine system; biomarkers

Special Issue Information

Dear Colleagues,

Concerning the post-COVID patients, personalized medicine is of significant medical interest. The identification of biomarkers that could guide the personalized approach of these patients could allow for the identification of the most effective diagnosis and treatment methods.

The Special Issue entitled "Personalized Medicine in Post-COVID-19 Era" of the Journal of Personalized Medicine will highlight the importance of understanding the main factors that influence individual responses to the virus and lead to more targeted and effective treatment strategies. In addition, it will focus on why certain individuals are more prone to long COVID and how to manage their symptoms more effectively. We hope that research tools such as proteomics, genomics, metabolomics and epigenomics will allow for the identification of guidelines for a personalized approach, and could help identify the patients who may need alternative vaccination strategies. Personalized medicine can help in identifying existing drugs that may be more effective for certain subgroups of COVID-19 patients, leading to potential drug repurposing for better outcomes. It is important to note that the field of personalized medicine is continuously evolving, and new research and developments are likely to emerge as more data are collected and analyzed.

Prof. Dr. Cristian Oancea
Dr. Elena Cojocaru
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • long COVID management
  • vaccine development
  • risk assessment
  • rehabilitation
  • public health approach
  • laboratory diagnosis
  • drug development and repurposing
  • genetic factor
  • proteomics
  • genomics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 304 KiB  
Review
Impact of COVID-19 on Pediatric Inflammatory Bowel Diseases—From Expectations to Reality
by Laura Mihaela Trandafir, Elena Lia Spoiala, Gabriela Ghiga, Nicoleta Gimiga, Paula-Diana Budescu, Vasile Valeriu Lupu, Lacramioara Butnariu, Elena Cojocaru and Gabriela Paduraru
J. Pers. Med. 2024, 14(4), 399; https://doi.org/10.3390/jpm14040399 - 09 Apr 2024
Viewed by 988
Abstract
Viral infections have always been considered a threat to global health, with numerous outbreaks across time. Despite the relative recent experience with coronavirus-associated diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe acute respiratory syndrome-2’s (SARS-CoV-2) continuous [...] Read more.
Viral infections have always been considered a threat to global health, with numerous outbreaks across time. Despite the relative recent experience with coronavirus-associated diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe acute respiratory syndrome-2’s (SARS-CoV-2) continuous evolution displays a different behavior. With a tropism for both respiratory and digestive mucosa, coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) seem to share a particular common background. Current literature offers evidence that viral alteration of the immune system, inflammatory intestinal tissue damage, increased intestinal permeability, incomplete viral clearance with viral antigen persistence, and intestinal dysbiosis, might explain SARS-CoV-2–IBD relationship in terms of etiopathogenesis and evolution. The hyperinflammatory state that both entities have in common explains the lack of success of current IBD therapy, raising the need for new personalized therapeutic options, with better outcomes for IBD and COVID-19 as well. This review aims to summarize the current available data on pediatric IBD evolution, management, and outcomes in the post-COVID period, with an emphasis on the particular aspects of the SARS-CoV-2–IBD relationship in children. Full article
(This article belongs to the Special Issue Personalized Medicine in Post-COVID-19 Era)
17 pages, 912 KiB  
Review
Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment
by Elena Cojocaru, Tudor Cojocaru, Giulia Mihaela Pînzariu, Ioana Vasiliu, Ioana Armașu and Cristian Cojocaru
J. Pers. Med. 2024, 14(1), 51; https://doi.org/10.3390/jpm14010051 - 29 Dec 2023
Viewed by 1248
Abstract
Pulmonary fibrosis, a critical outcome of chronic inflammatory diseases, has gained prominence in the context of post-coronavirus (post-COVID-19) complications. This review delves into the multifaceted landscape of post-COVID-19 pulmonary fibrosis, elucidating the intricate molecular mechanisms underlying its pathogenesis and highlighting promising therapeutic avenues. [...] Read more.
Pulmonary fibrosis, a critical outcome of chronic inflammatory diseases, has gained prominence in the context of post-coronavirus (post-COVID-19) complications. This review delves into the multifaceted landscape of post-COVID-19 pulmonary fibrosis, elucidating the intricate molecular mechanisms underlying its pathogenesis and highlighting promising therapeutic avenues. Examining the aftermath of severe acute respiratory syndrome-2 (SARS-CoV-2) infection, the review reveals key signaling pathways implicated in the fibrotic cascade. Drawing parallels with previous coronavirus outbreaks enhances our understanding of the distinctive features of post-COVID-19 fibrosis. Antifibrotic drugs, like pirfenidone and nintedanib, take center stage; their mechanisms of action and potential applications in post-COVID-19 cases are thoroughly explored. Beyond the established treatments, this review investigates emerging therapeutic modalities, including anti-interleukin agents, immunosuppressants, and experimental compounds, like buloxybutide, saracatinib, sirolimus, and resveratrol. Emphasizing the critical importance of early intervention, this review highlights the dynamic nature of post-COVID-19 pulmonary fibrosis research. In conclusion, the synthesis of current knowledge offers a foundation for advancing our approaches to the prevention and treatment of these consequential sequelae of COVID-19. Full article
(This article belongs to the Special Issue Personalized Medicine in Post-COVID-19 Era)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop